Accuracy of the InnowaveDX MTB/RIF test for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre study
ABSTRACTEarly and accurate diagnosis of tuberculosis (TB) is necessary to initiate proper therapy for the benefit of the patients and to prevent disease transmission in the community. In this study, we developed the InnowaveDX MTB/RIF (InnowaveDX) to detect Mycobacterium tuberculosis (MTB) and rifampicin resistance simultaneously. A prospective multicentre study was conducted to evaluate the diagnostic performance of InnowaveDX for the detection MTB in sputum samples as compared with Xpert and culture. The calculated limit of detection (LOD) for InnowaveDX was 9.6 CFU/ml for TB detection and 374.9 CFU/ml for RIF susceptibility. None of the other bacteria tested produced signals that fulfilled the positive TB criteria, demonstrating a species-specificity of InnowaveDX. Then 951 individuals were enrolled at 7 hospitals, of which 607 were definite TB cases with positive culture and/or Xpert results, including 354 smear-positive and 253 smear-negative cases. InnowaveDX sensitivity was 92.7% versus bacteriologically TB standard. Further follow-up revealed that 61 (91.0%) out of 67 false-positive patients with no bacteriological evidence met the criteria of clinically diagnosed TB. Among 125 RIF-resistant TB patients diagnosed by Xpert, 108 cases were correctly identified by InnowaveDX, yielding a sensitivity of 86.4%. Additionally, the proportion of very low bacterial load in the discordant susceptibility group was significantly higher than in the concordant susceptibility group (P = 0.029). To conclude, we have developed a novel molecular diagnostic with promising detection capabilities of TB and RIF susceptibility. In addition, the discordant RIF susceptibility results between InnowaveDX and Xpert are more frequently observed in samples with very low bacterial load..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Emerging Microbes and Infections - 12(2023), 1 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yunfeng Deng [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
GeneXpert |
|---|
| doi: |
10.1080/22221751.2022.2151382 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ000488380 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ000488380 | ||
| 003 | DE-627 | ||
| 005 | 20240414125235.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/22221751.2022.2151382 |2 doi | |
| 035 | |a (DE-627)DOAJ000488380 | ||
| 035 | |a (DE-599)DOAJbd6a79766244487280e1cfb05023f605 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 050 | 0 | |a QR1-502 | |
| 100 | 0 | |a Yunfeng Deng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Accuracy of the InnowaveDX MTB/RIF test for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACTEarly and accurate diagnosis of tuberculosis (TB) is necessary to initiate proper therapy for the benefit of the patients and to prevent disease transmission in the community. In this study, we developed the InnowaveDX MTB/RIF (InnowaveDX) to detect Mycobacterium tuberculosis (MTB) and rifampicin resistance simultaneously. A prospective multicentre study was conducted to evaluate the diagnostic performance of InnowaveDX for the detection MTB in sputum samples as compared with Xpert and culture. The calculated limit of detection (LOD) for InnowaveDX was 9.6 CFU/ml for TB detection and 374.9 CFU/ml for RIF susceptibility. None of the other bacteria tested produced signals that fulfilled the positive TB criteria, demonstrating a species-specificity of InnowaveDX. Then 951 individuals were enrolled at 7 hospitals, of which 607 were definite TB cases with positive culture and/or Xpert results, including 354 smear-positive and 253 smear-negative cases. InnowaveDX sensitivity was 92.7% versus bacteriologically TB standard. Further follow-up revealed that 61 (91.0%) out of 67 false-positive patients with no bacteriological evidence met the criteria of clinically diagnosed TB. Among 125 RIF-resistant TB patients diagnosed by Xpert, 108 cases were correctly identified by InnowaveDX, yielding a sensitivity of 86.4%. Additionally, the proportion of very low bacterial load in the discordant susceptibility group was significantly higher than in the concordant susceptibility group (P = 0.029). To conclude, we have developed a novel molecular diagnostic with promising detection capabilities of TB and RIF susceptibility. In addition, the discordant RIF susceptibility results between InnowaveDX and Xpert are more frequently observed in samples with very low bacterial load. | ||
| 650 | 4 | |a Tuberculosis | |
| 650 | 4 | |a molecular diagnosis | |
| 650 | 4 | |a rpoB | |
| 650 | 4 | |a rifampicin | |
| 650 | 4 | |a GeneXpert | |
| 650 | 4 | |a InnowaveDX | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 653 | 0 | |a Microbiology | |
| 700 | 0 | |a Zichun Ma |e verfasserin |4 aut | |
| 700 | 0 | |a Biyi Su |e verfasserin |4 aut | |
| 700 | 0 | |a Guanghong Bai |e verfasserin |4 aut | |
| 700 | 0 | |a Jianhua Pan |e verfasserin |4 aut | |
| 700 | 0 | |a Quan Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Long Cai |e verfasserin |4 aut | |
| 700 | 0 | |a Yanhua Song |e verfasserin |4 aut | |
| 700 | 0 | |a Yuanyuan Shang |e verfasserin |4 aut | |
| 700 | 0 | |a Pinyun Ma |e verfasserin |4 aut | |
| 700 | 0 | |a Jing Li |e verfasserin |4 aut | |
| 700 | 0 | |a Qianxuan Zhou |e verfasserin |4 aut | |
| 700 | 0 | |a Gulibike Mulati |e verfasserin |4 aut | |
| 700 | 0 | |a Dapeng Fan |e verfasserin |4 aut | |
| 700 | 0 | |a Shanshan Li |e verfasserin |4 aut | |
| 700 | 0 | |a Yaoju Tan |e verfasserin |4 aut | |
| 700 | 0 | |a Yu Pang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Emerging Microbes and Infections |d Taylor & Francis Group, 2013 |g 12(2023), 1 |w (DE-627)DOAJ00011538X |x 22221751 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:1 |
| 856 | 4 | 0 | |u https://doi.org/10.1080/22221751.2022.2151382 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/bd6a79766244487280e1cfb05023f605 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.tandfonline.com/doi/10.1080/22221751.2022.2151382 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2222-1751 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 1 | ||